Nina Toft
Overview
Explore the profile of Nina Toft including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
234
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Taalas T, Oskarsson T, Heyman M, Lund B, Lepik K, Vaitkeviciene G, et al.
Haematologica
. 2025 Feb;
PMID: 39973352
Age and sex have historically been associated with differences in acute lymphoblastic leukemia (ALL) survival. In the NOPHO ALL2008 trial, patients aged 1-45 years with BCR::ABL1-negative B-precursor and Tcell ALL...
2.
Kristensen D, Jatun T, Simonsen M, Toft N, Dimitrijevic A, Orskov A, et al.
Eur J Cancer
. 2024 Sep;
212:114338.
PMID: 39326288
Background: Previous studies have shown continuous improved overall survival (OS) up to 2015 for young adults with acute lymphoblastic leukaemia (ALL). However, recently several important advances have been made justifying...
3.
Glenthoj A, Rasmussen A, Bendtsen S, Hasle H, Hoffmann M, Rieneck K, et al.
Orphanet J Rare Dis
. 2024 Jul;
19(1):284.
PMID: 39085840
Background: Hereditary anemias are a group of genetic diseases prevalent worldwide and pose a significant health burden on patients and societies. The clinical phenotype of hereditary anemias varies from compensated...
4.
Glenthoj A, van Beers E, van Wijk R, Rab M, Groot E, Vejlstrup N, et al.
BMJ Open
. 2024 Jul;
14(7):e083691.
PMID: 39079928
Introduction: Membranopathies encompass haemolytic disorders arising from genetic variants in erythrocyte membrane proteins, including hereditary spherocytosis and stomatocytosis. Congenital dyserythropoietic anaemia type II (CDA II) is associated with the gene...
5.
Egnell C, Hallbook H, Heyman M, Wartiovaara-Kautto U, Quist-Paulsen P, Schmiegelow K, et al.
Acta Oncol
. 2023 Sep;
62(12):1723-1731.
PMID: 37725524
Background: Data on outcome for patients in different body mass index (BMI) categories in young adults with acute lymphoblastic leukemia (ALL) are scarce. We explored survival and toxicities in different...
6.
Gjaerde L, Rank C, Klarskov Andersen M, Jakobsen L, Sengelov H, Olesen G, et al.
Leuk Lymphoma
. 2021 Oct;
63(2):416-425.
PMID: 34672245
We investigated trends of survival in a population-based cohort study of all 181 adults who received HCT for ALL in Denmark between 2000-2019. Patients had a median (min-max) age of...
7.
Toksvang L, Andres-Jensen L, Rank C, Niinimaki R, Nersting J, Nygaard Nielsen S, et al.
Cancer Chemother Pharmacol
. 2021 Jun;
88(5):911-917.
PMID: 34145469
Purpose: Osteonecrosis is a burdensome treatment-related toxicity that is mostly diagnosed during or soon after 6-mercaptopurine (6MP)/methotrexate (MTX) maintenance therapy for acute lymphoblastic leukemia (ALL), possibly indicating a pathogenic role...
8.
Glenthoj A, Samson M, Toft N, Diness B, Askj R N, Vojdeman F, et al.
Ugeskr Laeger
. 2021 Jan;
183(3).
PMID: 33491643
The prevalence of people in Denmark descending from areas with a high prevalence of haemoglobinopathies is approximately one tenth and increasing. Since 1995, the Danish Health Authority has recommended haemoglobinopathy...
9.
Rank C, Stensig Lynggaard L, Als-Nielsen B, Stock W, Toft N, Nielsen O, et al.
Cochrane Database Syst Rev
. 2020 Oct;
10:CD013399.
PMID: 33038027
Background: The risk of venous thromboembolism is increased in adults and enhanced by asparaginase-based chemotherapy, and venous thromboembolism introduces a secondary risk of treatment delay and premature discontinuation of key...
10.
Rank C, Wolthers B, Grell K, Albertsen B, Frandsen T, Overgaard U, et al.
J Clin Oncol
. 2019 Nov;
38(2):145-154.
PMID: 31770057
Purpose: Asparaginase-associated pancreatitis (AAP) is common in patients with acute lymphoblastic leukemia (ALL), but risk differences across age groups both in relation to first-time AAP and after asparaginase re-exposure have...